Short‐ and medium‐term outcomes following primary ileocaecal resection for Crohn’s disease in two specialist centres. BJS 2017; 104: 1713-1722.
Published: 26th July 2017
Authors: A. de Buck van Overstraeten, E. J. Eshuis, S. Vermeire, G. Van Assche, M. Ferrante, G. R. D'Haens et al.
Despite improvements in medical therapy, the majority of patients with Crohn's disease still require surgery. The aim of this study was to report safety, and clinical and surgical recurrence rates, including predictors of recurrence, after ileocaecal resection for Crohn's disease.
This was a cohort analysis of consecutive patients undergoing a first ileocaecal resection for Crohn's disease between 1998 and 2013 at one of two specialist centres. Anastomotic leak rate and associated risk factors were assessed. Kaplan–Meier estimates were used to describe long‐term clinical and surgical recurrence. Univariable and multivariable regression analyses were performed to identify risk factors for both endpoints.
In total, 538 patients underwent primary ileocaecal resection (40·0 per cent male; median age at surgery 31 (i.q.r. 24–42) years). Median follow‐up was 6 (2–9) years. Fifteen of 507 patients (3·0 per cent) developed an anastomotic leak. An
Ileocaecal resection achieved durable medium‐term remission, but smoking and resection margin positivity were risk factors for recurrence.Read more
You may also be interested in
Authors: M.E. Kelly, R. Glynn, A.G.J. Aalbers, M. Abraham‐Nordling, W. Alberda, A. Antoniou et al.
Notes: Complete resection is key
Randomized clinical trial
Randomized clinical trial of intracutaneously versus transcutaneously sutured ileostomy to prevent stoma‐related complications (ISI trial).
Authors: M. F. Sier, D. D. Wisselink, D. T. Ubbink, R. J. Oostenbroek, G. J. Veldink, B. Lamme et al.
Notes: More leaks with intracutaneous
Authors: S. J. Chapman, A. Pericleous, C. Downey, D. G. Jayne
Notes: No easy answers.
Randomized clinical trial
Authors: E. M. de Leede, N. J. van Leersum, H. M. Kroon, V. van Weel, J. R. M. van der Sijp, B. A. Bonsing et al.
Notes: Chewing gum no effect on recovery
Authors: E. J. Ryan, E. M. Creagh
Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. BJS 2018; 105: e192-e203.
Authors: F. C. Koyama, C. M. Lopes Ramos, F. Ledesma, V. A. F. Alves, J. M. Fernandes, B. B. Vailati et al.
Notes: Molecular enhancement of treatment
Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. BJS 2018; 105: e99-e109.
Authors: K. M. Marks, N. P. West, E. Morris, P. Quirke
Notes: Defines modern practice
Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery. BJS 2018; 105: e131-e141.
Authors: S. Gaines, C. Shao, N. Hyman, J. C. Alverdy
Notes: A neglected frontier
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. BJS 2018; 105: e204-e211.
Authors: I. Ubink, W. J. van Eden, P. Snaebjornsson, N. F. M. Kok, J. van Kuik, W. M. U. van Grevenstein et al.
Notes: Mesenchymal subtype predominates
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth
Preliminary results of a cohort study of induction chemotherapy‐based treatment for locally recurrent rectal cancer. BJS 2018; 105: 447-452.
Authors: D. M. G. I. van Zoggel, S. J. Bosman, M. Kusters, G. A. P. Nieuwenhuijzen, J. S. Cnossen, G. J. Creemers et al.
Notes: Promising responses